Actualités Conduit Pharmaceuticals Inc - CDT | Actions NASDAQ

Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit...

Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

Conduit Pharmaceuticals strengthens its Board of Directors with the addition of Simon Fry, a seasoned investment banking executive with over 30...

Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes

SAN DIEGO and LONDON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced...

Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SAN DIEGO and LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced...

Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders

Conduit Pharmaceuticals announces plans to initiate Phase 2a trials in both systemic lupus erythematosus and ANCA-associated vasculitis for its...

Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments

Conduit Pharmaceuticals enters into exclusive license agreement with AstraZeneca for HK-4 Glucokinase activators AZD1656 and AZD5658 targeting...

Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

SAN DIEGO and LONDON, July 16, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or...

Conduit Pharmaceuticals to Join Russell 3000® Index

SAN DIEGO and LONDON, June 13, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (the “Company” or “Conduit"), today announced...

A Presidio Property Trust Major Investment To Be Part of Russell 2000®

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Presidio Property Trust, Inc. (NASDAQ: SQFT; SQFTP; SQFTW...

Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer

Conduit also appoints prominent intellectual property attorney Jeffrey Lindeman as a Consultant Leadership additions underscore Conduit’s...

Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe’s Leading Life Sciences Hub

SAN DIEGO and LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit...

Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

SAN DIEGO and LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit"), a multi-asset, clinical-stage...

Conduit Pharmaceuticals to Participate in the 14th Annual Jefferies London Healthcare Conference

SAN DIEGO and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit Pharmaceuticals” or “Conduit”), a...

Conduit Pharmaceuticals Partners with ClinConnect on Cocrystal Development Program for AZD1656

SAN DIEGO and LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit Pharmaceuticals” or “Conduit”), a...

Presidio Property Trust Announces Closing of Merger of Its Sponsored SPAC Murphy Canyon Acquisition Corp Now Trading as Conduit Pharmaceuticals (Nasdaq: CDT and CDTTW)

Presidio’s sponsored SPAC completed its previously announced business combination with Conduit Pharmaceuticals, Inc.Conduit now trades on the...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Conduit Pharmaceuticals Inc (CDT)

Votre Hub pour des idées et discussions en direct en temps réel

CDT Actualités

Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders

Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes

Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders

Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments

Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Conduit Pharmaceuticals to Join Russell 3000® Index

A Presidio Property Trust Major Investment To Be Part of Russell 2000®

Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer

Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe’s Leading Life Sciences Hub

Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Conduit Pharmaceuticals to Participate in the 14th Annual Jefferies London Healthcare Conference

Conduit Pharmaceuticals Partners with ClinConnect on Cocrystal Development Program for AZD1656

Presidio Property Trust Announces Closing of Merger of Its Sponsored SPAC Murphy Canyon Acquisition Corp Now Trading as Conduit Pharmaceuticals (Nasdaq: CDT and CDTTW)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Conduit Pharmaceuticals Inc (CDT) Actualités

Conduit Pharmaceuticals Inc (CDT)

Votre Hub pour des idées et discussions en direct en temps réel

CDT Actualités

Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders

Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes

Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders

Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments

Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Conduit Pharmaceuticals to Join Russell 3000® Index

A Presidio Property Trust Major Investment To Be Part of Russell 2000®

Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer

Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe’s Leading Life Sciences Hub

Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Conduit Pharmaceuticals to Participate in the 14th Annual Jefferies London Healthcare Conference

Conduit Pharmaceuticals Partners with ClinConnect on Cocrystal Development Program for AZD1656

Presidio Property Trust Announces Closing of Merger of Its Sponsored SPAC Murphy Canyon Acquisition Corp Now Trading as Conduit Pharmaceuticals (Nasdaq: CDT and CDTTW)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application